Ticker LaunchIPO · FULC
Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. (FULC) priced its initial public offering on Jul 18, 2019 at $16.00 per share, raising $72M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $373.4M. WilmerHale advised the company and Ropes & Gray advised the underwriters.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on genetically defined rare diseases. It uses a product engine to identify drug targets that modulate gene expression, and its candidate losmapimod is headed for a Phase 2b trial in facioscapulohumeral muscular dystrophy, with programs in sickle cell disease and beta-thalassemia.
- Status
- IPO
- Ticker
- FULC
- Exchange
- Nasdaq Global Market
- Priced
- Jul 18, 2019
- IPO price
- $16.00
- Raised
- $72M
- Market cap at IPO price
- $373.4M
- First filed
- Jun 21, 2019
- Company counsel
- WilmerHale
- Underwriters' counsel
- Ropes & Gray
- Sector
- Biotech & pharma
- Country / state
- MA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jun 21, 2019
- Latest amendment Jul 12, 2019
- Final prospectus (424B4) Jul 18, 2019
- All filings on EDGAR CIK 1680581
Other Biotech & pharma IPOs in 2019
- SNDL Inc.SNDL · Aug 1, 2019
- Genmab A/SGMAB · Jul 19, 2019 · $505.9M
- Mirum Pharmaceuticals, Inc.MIRM · Jul 18, 2019 · $75M
- BridgeBio Pharma, Inc.BBIO · Jun 28, 2019 · $348.5M
- Karuna Therapeutics, Inc.KRTX · Jun 28, 2019 · $89.2M
- Adaptive Biotechnologies CorpADPT · Jun 27, 2019 · $300M